Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy by Rui Miguel Pedrosa Pereira
 i 
 
 
 
 
 
 
 
 
Safety of Anti-TNF Therapies in Immune-
Mediated Inflammatory Diseases: Focus on 
Infections and Malignancy 
 
 
 
 
Rui Miguel Pedrosa Pereira 
DISSERTAÇÃO DE MESTRADO INTEGRADO EM MEDICINA 
2016  
 i 
 
ARTIGO DE INVESTIGAÇÃO 
MESTRADO INTEGRADO EM MEDICINA 
INSTITUTO DE CIÊNCIAS BIOMÉDICAS ABEL SALAZAR UNIVERSIDADE DO PORTO 
CENTRO HOSPITALAR DO PORTO 
 
 
Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory 
Diseases: Focus on Infections and Malignancy 
 
AUTOR: Rui Miguel Pedrosa Pereira, 
estudante do 6º ano do Mestrado Integrado em 
Medicina no Instituto de Ciências Biomédicas 
Abel Salazar – Universidade do Porto, 
Portugal, contacto: ppereira.rui@gmail.com 
 
ORIENTADOR: Professor Doutor Tiago da 
Costa Ferreira Torres, Médico, 
Dermatologista, Assistente Hospitalar 
Graduado, Serviço de Dermatologia – Centro 
Hospitalar do Porto; Instituto de Ciências 
Biomédicas Abel Salazar – Universidade do 
Porto. 
 
2016 
  
  
ii 
 
AGRADECIMENTOS 
Ao Professor Doutor Tiago Torres agradeço por todas as orientações e incentivos dados 
durante estes dois últimos anos, que permitiram a realização deste trabalho, o qual 
ultrapassou por completo as expectativas iniciais. 
À Professora Doutora Margarida Lima agradeço a oportunidade de frequentar a Disciplina 
de Iniciação à Investigação Clínica, por todos os conhecimentos teórico-práticos adquiridos 
e ajudas obtidas na realização deste projeto. 
À Doutora Isabel Fonseca agradeço pelo tempo despendido e ajuda no que toca à análise 
estatística.  
À Dra. Paula Lago e Dra. Raquel Faria agradeço a oportunidade de tornar este projeto 
multidisciplinar e, de maior relevo. 
À Mafalda agradeço pelas críticas construtivas e ajuda em aperfeiçoar este trabalho. 
Por fim, agradeço a todos os meus colegas que me acompanharam ao longo destes 6 anos 
de curso. 
 
 
  
  
iii 
 
NOTA INTRODUTÓRIA 
A presente dissertação de mestrado, apresentada na modalidade “Artigo de Investigação”, 
resultou de um projeto de investigação desenvolvido no âmbito da unidade curricular 
“Disciplina de Iniciação à Investigação Clínica” (DIIC) do Mestrado Integrado em Medicina 
do Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto. 
A proposta de projeto foi elaborada no ano letivo de 2014/2015, tendo sido submetida e 
aprovada pela Comissão de Ética e pelo Gabinete Coordenador da Investigação do 
Departamento de Ensino, Formação e Investigação, e autorizada pelo Conselho de 
Administração do Centro Hospitalar do Porto [2015.120(107-DEFI/100-CES)]. 
O projeto foi realizado no Serviço de Dermatologia, no ano letivo 2015/2016, sob a 
orientação do Professor Doutor Tiago Torres, com a supervisão da Professora Doutora 
Margarida Lima, regente da DIIC. 
Do projeto resultaram: um artigo científico de revisão publicado na revista Drug 
Development Research, dois artigos científicos originais para publicação e um trabalho 
apresentado, na forma de poster, nas XXVIII Jornadas de Terapêutica. 
A dissertação encontra-se estruturada em quatro partes: 
1. Artigo de revisão “Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory 
Diseases: Focus on Infections and Malignancy” publicado na revista Drug Development 
Research; 
2. Artigo original “Assessment of hepatitis B reactivation in patients treated with anti-
TNF therapy with past HBV exposure” submetido para publicação na revista Internal 
Medicine Journal; 
3. Artigo original “Infection and malignancy risk in patients treated with TNF inhibitors 
for immune-mediated inflammatory diseases” para publicação em revista científica da 
área; 
4. Trabalho apresentado na forma de poster nas XXVIII Jornadas de Terapêutica. 
Como apêndice é apresentada a proposta do projeto de investigação, tal como foi 
aprovada, e como anexos, os respetivos documentos de submissão e autorização. 
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INTRODUÇÃO 
O conceito de doenças inflamatórias imunomediadas engloba um vasto leque de patologias 
crónicas, altamente incapacitantes, que, embora não estejam clinicamente relacionadas, 
partilham uma desregulação do sistema imunológico na qual a inflamação tem um papel 
central. Estima-se que, coletivamente, afetem até 7% da população ocidental. O tratamento 
destas doenças incide sobre o controlo da inflamação e prevenção do dano tecidular com 
o objetivo de remissão a longo prazo, melhorando a qualidade de vida. Os inibidores do 
fator de necrose tumoral (anti-TNF) estão aprovados no tratamento de várias doenças 
inflamatórias imunomediadas incluindo a doença inflamatória intestinal, artrite reumatóide, 
psoríase e artrite psoriática, espondilite anquilosante e artrite idiopática juvenil, modificando 
o prognóstico das mesmas. Atualmente existem 5 agentes anti-TNF (infliximab, 
adalimumab, etanercept, certolizumab pegol e golimumab) que possuem indicações 
terapêuticas diferentes. 
Apesar de estes agentes terem mais de uma década de uso clínico em diversas patologias, 
existem ainda resultados inconsistentes no que toca ao perfil de segurança. Em relação 
aos eventos adversos infeciosos existem, de facto, estudos que mostram um aumento na 
taxa de infeção grave, enquanto outros negam esse achado. O fator de necrose tumoral 
possui um papel chave na formação de granulomas e, como tal, existe um risco 
reconhecido de reativação de tuberculose latente. Este ponto é particularmente importante 
visto que esta infeção tem uma relevância central na realidade portuguesa. Os estudos 
mais recentes não associam os anti-TNF a um risco aumentado de tumores sólidos ou 
hematológicos com a exceção de neoplasias cutâneas (incluindo melanoma). 
Tanto quanto apuramos, não existem estudos a comparar o risco destes efeitos adversos 
nas diferentes doenças inflamatórias imunomediadas. O objetivo deste estudo retrospetivo 
é descrever a experiência de um hospital terciário relativamente aos efeitos adversos 
infeciosos e malignos durante terapêuticas anti-TNF. Tanto quanto sabemos este é o 
primeiro estudo do género em Portugal, principalmente com uma amostra abrangente de 
todas as áreas clínicas que utilizam agentes anti-TNF e com um período observacional tão 
alargado. 
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Assessment of hepatitis B reactivation in patients with past HBV exposure 
treated with anti-TNF therapy 
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2- Department of Dermatology, Centro Hospitalar do Porto, Portugal 
3- Clinical Immunology Unit, Centro Hospitalar do Porto, Portugal 
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Abstract 
Background: The risk of hepatitis B virus (HBV) reactivation in patients with past exposure to HBV (positive 
antibodies to hepatitis B core antigen (anti-HBc), negative hepatitis B surface antigen (HBsAg) and HBV-DNA, 
with or without antibodies to hepatitis B surface antigen (anti-HBs)] treated with anti-tumor necrosis factor (anti-
TNFα) agents is uncertain. Aims: The aim of the present study was to evaluate the safety of anti-TNFα therapy 
in anti-HBc positive/HBsAg negative patients with any indication for this biologic therapy. Methods: Anti-HBc 
positive/HBsAg negative subjects treated for immune-mediated inflammatory diseases (IMIDs) with anti-TNFα 
(Infliximab, Adalimumab, Etanercept and Golimumab) from January 2000 to December 2014 in a Tertiary 
Hospital were included. Results: From a total of 389 patients that were treated with anti-TNFα, 26 patients had 
serologic profile compatible with a previous HBV infection. The mean observation time was 43.6 ± 28.7 months. 
No case of reactivation was detected regardless of anti-HBs positivity (no increase in aminotransferases above 
normal range, de novo detection of HBV-DNA or HBsAg seroconversion). Conclusion: This retrospective study 
supports the available data regarding the safety of anti-TNFα therapy in patients with HBV past exposure. 
 
Keywords: anti-TNFα, HBV reactivation, past exposure, Immune-mediated inflammatory disease 
 
Introduction 
Anti-tumor necrosis factor (anti-TNFα) agents 
revolutionized the treatment of inflammatory diseases 
such as psoriasis, spondyloarthropathies, rheumatoid 
arthritis and inflammatory bowel disease (IBD). 
However given their immunosuppressive nature, 
these agents increase susceptibility to new infections 
and alter the natural course of latent infections such 
as Hepatitis B virus (HBV) (1-3).  
Hepatitis B infection can be classified in different 
disease stages depending on the interpretation of the 
analytic and serologic profile of each patient (4). 
Occult HBV infection is defined as the persistence of 
viral genome in the liver tissue of individuals 
serologically negative for hepatitis B surface antigen 
(HBsAg). Due to the difficulty in identifying HBV-DNA 
through liver biopsy and the rarity of detectable serum 
viremia, some consider patients with positive 
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antibodies to hepatitis B core antigen (anti-HBc), 
negative HBsAg and HBV-DNA, with or without 
antibodies to hepatitis B surface antigen (anti-HBs) as 
potential occult HBV carriers (5). 
In patients with positive HBsAg, antiviral prophylaxis 
is required before biological treatment is initiated (6). 
In the group of patients with past HBV infection 
(positive anti-HBc and negative HBsAg), an unknown 
percentage may carry an occult infection and 
reactivate upon exposure to the immunosuppressive 
therapy (7, 8). Studies in subjects with past HBV 
infection treated with anti-TNFα therapy for 
inflammatory bowel disease and rheumatic diseases 
estimated a reactivation rate between 1.7% and 5% of 
patients (7, 8). 
The aim of this retrospective study was to evaluate the 
rate of reactivation in anti-HBc positive/HBsAg 
negative patients treated with anti-TNFα agents for 
psoriasis, rheumatologic diseases and inflammatory 
bowel diseases. 
 
Methods 
Patients treated for Immune-mediated inflammatory 
diseases (IMIDs) such as psoriasis, psoriatic arthritis, 
ankylosing spondylitis, juvenile idiopathic arthritis, 
rheumatoid arthritis, Crohn’s disease and ulcerative 
colitis with anti-TNFα (Infliximab, Adalimumab, 
Etanercept and Golimumab) from January 2000 to 
December 2014, for at least a month, in a Tertiary 
Hospital were included. Information regarding the 
patients’ hepatitis B screening serology (HBsAg, anti-
HBc, anti-HBs) and HBV-DNA (in anti-HBc positive 
patients) prior to the initiation of immunosuppressive 
therapy as well as HBsAg seroconversion, HBV-DNA 
de novo detection and ALT/AST levels during anti-
TNF therapy were collected. HBV reactivation was 
defined on the basis of a titer elevation of 2 to 3 times 
the upper limit of normal of ALT, in combination with 
de novo detection of HBV-DNA or an increase over 
10-fold of the HBV-DNA relative to the title before the 
initiation of therapy or HBsAg seroconversion. 
Furthermore, the patients clinical and demographic 
characteristics such as age, gender, disease duration, 
treatment [anti-TNFα in monotherapy or combined 
with corticosteroids and/or other 
immunosuppressant’s [methotrexate, azathioprine] 
and treatment duration were recorded. 
 
Results 
From a total of 389 patients that were treated with anti-
TNFα biologics from January 2000 to December 2014, 
292 (75%) were screened before the initiation of 
treatment while the remaining 97 (25%) had no 
recorded pre-treatment screening. In patients in which 
a pre-treatment screening was performed, 237 (81%) 
had no positive marker, 28 (10%) were only anti-HBs 
positive (previous immunization), 26 (9%) patients 
were anti-HBc positive/HBsAg negative and one 
patient presented with a serologic profile compatible 
with chronic hepatitis B. 
The mean observation time was 43.6 ± 28.7 months. 
Demographic as well as clinical baseline parameters 
of the subjects are reported in Table 1. Among the 26 
anti-HBc positive/HBsAg negative patients, 19 
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(73.1%) were anti-HBs positive in the pre-
treatment screening. During the observational 
period 3 (11.5%) other patients were found to 
be anti-HBs positive. HBV-DNA levels were 
only available in 7 out of 26 (26.9%) patients 
nonetheless they were, when present, 
undetectable at enrolment. Additionally, 
during follow up, HBV-DNA levels were 
measured in 7 additional patients amounting 
to 14/26 (53.8%) patients with undetectable 
HBV-DNA levels. At baseline, the values of 
aminotransferases (AST and ALT) were within 
the normal range and values above normal 
range were not observed during the 
observational period. At the end of the 
observational period, no case of reactivation was 
observed in anti-HBc positive/HBsAg negative 
patients regardless of anti-HBs positivity.  
 
Discussion 
HBV reactivation is a well-known risk in HBsAg 
positive patients treated with a wide variety of 
immunosuppressive therapies such those used in 
hematopoietic stem cell transplantation, 
corticosteroids, anthracyclines and rituximab in 
addition to anti-TNFα agents. Patients with past HBV 
infection can arbor an occult infection, and thus, be 
susceptible to reactivation when exposed to 
immunosuppression. Depending on the inflammatory 
pathways they suppress or modulate, 
immunosuppressive agents of different classes have 
shown to be responsible for different absolute risks of 
latent infection reactivation (9). It is largely accepted 
that anti-TNFα agents may lead to HBV reactivation in 
this subset of patients, although in a recent meta-
analysis involving patients with rheumatologic and 
dermatologic conditions, reactivation rates were found 
to be much lower when compared to HBsAg positive 
patients. (10). 
The prevalence of anti-HBc positive/HBsAg negative 
patients was 9% in the present study. Previous 
studies in patients with chronic inflammatory 
arthropathies treated with anti-TNFα identified a 9- 2% 
prevalence of anti-HBc positive/ HBsAg negative 
patients (2, 11). Some studies that took place in higher 
prevalence areas detected even higher rates.(12, 13). 
In the present study, the biological treatment caused 
no apparent reactivation of hepatitis B virus. Most 
studies regarding this subject were undertaken in 
patients treated with anti-TNFα for rheumatoid arthritis 
and/or spondyloarthropathies and, in concordance 
with the present study, reported no reactivations (2, 
11, 14-16). Likewise a retrospective study involving 13 
Table 1 - Baseline characteristics of 26 anti-HBc positive/ 
HBsAg negative patients 
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patients with Psoriasis showed no reactivations (1). 
To the authors’ knowledge there are no studies 
focusing on anti-HBc positive/HBsAg negative 
patients treated anti-TNF therapy for IBD. Pérez-
Alvarez et al. in a systematic review analyzed 168 
anti-HBc positive/HBsAg negative patients in studies/ 
case reports of patients with RA, 
spondyloarthropathies, psoriasis as well as IBD. HBV 
was reactivated in 9 out of those 168 patients (5,4%) 
(7).  A meta-analysis by Lee et al. covered 9 clinical 
studies summing up to 468 anti-HBc positive/ HBsAg 
negative patients treated with anti-TNFα for 
rheumatologic diseases. In 5 of the 9 clinical studies 
no HBV reactivation was detected. HBV reactivation 
was observed in 8/468 patients (1.7%) with a 
percentage of HBV reactivation ranging from 0 to 
8.3% (8). Given the reported risk of reactivation in 
previous studies using anti-TNFα which can lead to 
serious life-threatening complications through disease 
flare that may lead to hepatic insufficiency, close 
monitoring of this patient group should be advised. 
In this study, all patients that had HBV DNA measured 
during screening, maintained their levels below 
detection threshold during follow up. The above 
mentioned studies had similar results concerning the 
lack of HBV-DNA positivity at baseline (2, 11, 14-16). 
There has been at least one retrospective study that 
found detectable baseline viral loads in this subset of 
patients. Lan et al. identified measureable HBV-DNA 
levels in 4/12 (33.3%) anti-HBc positive/HBsAg 
negative patients in a study of rheumatoid arthritis 
patients in Southeast Asia (17). 
Although we registered no reactivation, there are 
studies that appear to indicate that the title of anti-HBs 
influences the risk of reactivation of hepatitis B virus. 
Kato et al. found that the 6 anti-HBc positive/HBsAg 
negative patients who experienced HBV reactivation 
had significantly lower baseline titers of anti-HBs (18). 
In the present study, 73.1% patients were anti-HBs 
positive in the pre-treatment screening and, by the 
end of the observational period, that number 
increased to 84.6%. The significance of this finding 
requires further studies.  
The present study presented some limitations, due to 
its retrospective nature and the relatively small patient 
sample. Patients with diverse IMIDs (Crohn’s disease, 
rheumatoid arthritis, ankylosing spondylitis, psoriasis 
and psoriatic arthritis) that were treated with anti-
TNFα biologics were included. Thus the analysis was 
not limited to a specific subgroup of patients therefore 
increasing the heterogeneity. Although there is a 
screening protocol in the authors’ hospital, some anti-
HBc positive/ HBsAg negative patients still have 
missing HBV-DNA levels and a deficiency in serologic 
follow up during anti-TNFα treatment.  
European Association for the Study of the Liver 
(EASL) guidelines state that candidates for 
chemotherapy and immunosuppressive therapy who 
are HBsAg positive should be tested for HBV-DNA 
levels and receive pre-emptive nucleotide analogues 
during therapy (regardless of HBV-DNA levels) and 
for 12 months after cessation of therapy (level of 
evidence A1). Furthermore, it is reported that most 
experience with pre-emptive treatment was with 
lamivudine. On the other hand, it is recommended that 
anti-HBc positive/ HBsAg negative patients with 
undetectable serum HBV-DNA, regardless of anti-
HBs status, who receive chemotherapy and/or 
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immunosuppression should be followed carefully by 
means of ALT and HBV-DNA testing and treated with 
NA therapy only upon confirmation of HBV 
reactivation before ALT elevation (level of evidence 
C1) (6). The use of lamivudine as a universal 
prophylactic therapy in this subset of patients has to 
be considered with caution. Benefits have to be 
pondered with care due to the risk of emergence of 
lamivudine-resistant mutants (19). 
The present study supports the thesis that treatment 
with anti-TNFα agents is relatively safe regarding the 
risk of HBV reactivation in anti-HBc positive/HBsAg 
negative patients. Nonetheless screening for HBV 
serologic markers prior to initiation of anti-TNFα 
therapy is of major importance since it may dictate 
which/ if any actions should be taken to minimize the 
risks related to hepatitis B infection (prophylactic 
treatment, vaccination or monitoring).  
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Abstract 
Background: Infectious and malignant events are responsible for significant morbidity and mortality in patients 
with Immune-Mediated Inflammatory Diseases (IMIDs). Anti-tumor necrosis factor (Anti-TNF) agents appear to 
have an impact, however the individual effect of these agents in the different conditions is still unclear. 
Objectives: To estimate the Incidence Rates (IR) of infections and malignancies in patients treated with anti-
TNFs across different IMIDs, as well as potential risk factors, in a Tertiary/University Hospital. Materials and 
Methods: IR/100 patient-years were evaluated in adult patients treated for any IMID with an anti-TNF between 
January 2000 and December 2014. Data was stratified according to agent, condition and site of infection. 
Predictor of infections/ malignancy were tested with bivariate and multivariate analysis. Results: Three hundred 
and forty-eight infections [277 (79.6%) non-serious, 71 (20.4%) serious] were reported, during the observational 
period in 171/387 (44.2%) patients. Thirty-one malignancies were diagnosed in 30/387 (7.8%) patients. 
Infections and malignancies were responsible for 8.3% and 13.1% of the cases of discontinuation of 
therapy/anti-TNF switch, respectively. The IR/100 patient-years of serious infections was 4.02 (95% CI 3.20-
5.04) ranging from 1.34 (95% CI 0.65-2.74) with etanercept to 6.82 (95% CI 5.12-9.03) with infliximab and from 
1.09 (95% CI 0.47-2.52) with psoriatic diseases to 6.63 (95% CI 5.06-8.63) with inflammatory bowel diseases. 
The most frequent site of serious infection was the gastrointestinal system. Five cases [IR of 0.28 (95% CI 0.12-
0.66) per 100 patient-years] of Tuberculosis were diagnosed, all in patients treated with monoclonal antibodies 
(infliximab and adalimumab). Three (60%) of those cases were extrapulmonary. The IR/100 patient-years of 
malignancy was 1.75 (95% CI 1.24-2-47) going from 1.17 (95% CI 0.57-2.50) with adalimumab to 2.17 (95% CI 
1.30-3.61) with infliximab and from 0.91 (95% CI 0.39-2.11) with inflammatory arthropathies to 2.39 (95% CI 
1.34-4.23) with psoriatic diseases. Methotrexate was significantly associated with a decrease in malignant risk 
in bi- and multivariate analysis. Conclusion: There is significant variability in the IR of infections and 
malignancies across indications and agents. Physicians should be thoughtful when generalizing data from 
literature regarding the use of an agent in a different indication. Further studies are necessary to clear aspects 
regarding the safety of individual anti-TNF biologics and to clarify their impact in the different IMIDs. 
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Introduction 
Immune-mediated inflammatory diseases (IMIDs) are 
a group of highly incapacitating, chronic conditions 
that share an immune dysregulation caused or 
accompanied by acute or chronic inflammation, albeit 
not being clinically related [Kuek et al. 2007; Williams 
and Meyers 2002]. It is estimated that collectively 
IMIDs affect 5% to 7% of the population in Western 
countries [Beyaert et al. 2013]. The treatment of this 
conditions focuses on the rapid control of 
inflammation, prevention of tissue damage, with the 
goal of long-term remission, thus improving quality of 
life.  
Anti-tumor necrosis factor (anti-TNF) therapies were 
first introduced into clinical practice in 1998 for the 
treatment of inflammatory bowel diseases (IBDs) and 
rheumatoid arthritis (RA). Since then anti-TNF 
biologics were approved for the treatment of several 
other IMIDs including psoriasis (Ps) and psoriatic 
arthritis (PsA), ankylosing spondylitis (AS) and 
juvenile idiopathic arthritis (JIA) changing the 
treatment and outcome of several of these conditions 
[Geiler et al. 2011]. 
Patients with chronic inflammatory diseases have, 
despite their treatment, an inherently higher risk of 
infection and malignancy for several disease-related 
reasons [Beyaert et al. 2013; Doran et al. 2002; 
Johnston et al. 2013]. There are, nonetheless 
concerns about the safety of anti-TNF agents which 
have been present since the introduction of these 
agents into clinical practice. Even though data 
concerning this subject is getting more robust from 
over a decade of treatment for diverse diseases there 
are still inconsistent results concerning the safety 
profile. In regard to infectious adverse events, for 
instance, some reports have shown an increase in the 
overall serious infection rate [Galloway et al. 2013; 
Komano et al. 2011]  while others denied it [Fouque-
Aubert et al. 2010; Leombruno and Keystone 2009; 
Peyrin–Biroulet et al. 2008]. Additionally, the risk of 
developing tuberculosis (TB) has been of special 
concern since TNF has an important biological role in 
the formation of granuloma and containment of the 
disease [Senaldi et al. 1996]. Regarding malignancy, 
earlier studies reported increased risk of lymphoma as 
well as malignancies overall [Bongartz et al. 2006; 
Wolfe and Michaud 2004]. On the other hand, more 
recent studies did not link anti-TNF biologics with an 
increased risk in solid or hematologic malignancies 
[Askling 2005a; Askling 2005b; Dommasch et al. 
2011; Keystone 2003; Leombruno and Keystone 
2009; Moulis et al. 2012; Peyrin–Biroulet et al. 2008; 
Saad et al. 2010; Wolfe and Michaud 2007b] the 
exception being melanoma and non-melanoma skin 
cancer (NMSC) [Askling et al. 2011; Wolfe and 
Michaud 2007a]. Even so, to the best of the authors’ 
knowledge, studies comparing the infectious/ 
malignant risk between different IMIDs are lacking 
[Pereira et al. 2015]. 
Adverse events such as infusion and injection-site 
reactions, autoimmunity, heart failure, neurological 
symptoms, demyelinating disease have also been 
reported [Chimenti et al. 2014; McLean and Cross 
2014; Murdaca et al. 2012]. Even so, the current 
retrospective observational study describes the 
experience of a tertiary/university hospital focusing in 
the development of infectious and malignant adverse 
events in association with the use of anti-TNF agents.  
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Materials and methods 
This retrospective observational study was conducted 
in a Tertiary/University Hospital. Patients were 
identified through each departments’ databases. All 
patients over 18 years old, who had an IMID diagnosis 
and received at least one month of anti-TNF treatment 
between January 2000 and December 2014 were 
included. Data was collected exclusively from the 
hospital’s medical records.  
Collected baseline data included patient 
demographics (gender and date of birth), underlying 
disease for which the anti-TNF was prescribed, the 
duration of the disease (defined as the time between 
diagnosis and the first anti-TNF treatment), smoking 
status and the presence of any comorbidity. During 
the observational period each patient could have been 
treated with one or more anti-TNF agent. Thus, 
information was gathered regarding every anti-TNF 
treatment (agent used, starting date, dosage, 
discontinuation date and along with the reason for 
cessation), whether switching occurred, the use of 
concomitant immunosuppressant treatments 
(corticosteroids, methotrexate, azathioprine et 
cetera). The anti-TNFs available for treatment during 
the observational period were Infliximab, 
Adalimumab, Etanercept and Golimumab. 
Discontinuation date was defined as the date of the 
first missed scheduled dose and duration of treatment 
as the time from initiation of anti-TNF therapy until 
discontinuation/switch or end of data collection [Dixon 
et al. 2007]. Furthermore, information from latent 
tuberculosis (LTB) screening [tuberculin skin test 
(TST), chest radiography, Interferon-Gamma Release 
Assays (IGRA)], tuberculosis prophylactic therapy, 
hepatitis B (HBV), hepatitis C (HCV) and human 
immunodeficiency virus (HIV) viral markers and 
vaccination (anti-influenza, anti-pneumococcal and 
others) was acquired.  
Adverse events (malignant and infectious) that 
occurred while the patients were treated with anti-TNF 
biologics were recorded together with their dates. 
Data regarding the adverse effects was considered 
not only when reported in medical records from 
outpatient visits but also from hospitalizations and 
emergency department visits. A “serious” infection 
was defined as any bacterial, viral, or fungal infection 
that required hospitalization, administration of 
appropriate intravenous antimicrobial therapy, 
temporary/ definitive withholding of anti-TNF 
treatment and/or led to death. Any other infectious 
event was classified as “non-serious”. Infectious 
events were divided into 5 patterns regarding the site 
of infection:  respiratory tract infections, including 
upper (nasopharyngitis, sinusitis, pharyngitis, 
tonsillitis and laryngitis) and lower (pneumonia and 
bronchitis) tract infections; urogenital infections, 
including cystitis, urethritis, pyelonephritis, prostatitis, 
salpingitis and oophoritis, pelvic inflammatory disease 
and sexually transmitted diseases; skin and soft tissue 
infections, including cellulitis, abscesses, wound 
infection, zoster, varicella, pyodermatitis and mycosis; 
digestive system infections including periapical 
abscess, oral and esophageal candidiasis, hepatic, 
intra-abdominal and rectal abscesses. The 5th pattern 
includes other, less frequently registered, infections 
such as eye and ear infections, joint and bone 
infections, neurological infections and septicemia of 
unknown origin. 
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Data collection was censored for each patient either 
at the time of anti-TNF discontinuation, disenrollment 
from the hospital or at the end of the observation 
period. This study was approved by the hospital’s 
Institutional Review Board. 
 
Statistical analysis 
Regarding descriptive statistics, continuous variables 
(age, duration of the disease at initiation of anti-TNF 
and anti-TNF treatment duration) are presented with 
mean and standard deviation. Frequencies and 
percentages were used to describe categorical patient 
characteristics. Incidence rates (IR) of infections, 
serious infections and malignancy are presented as 
event/100 patient-years with 95% confidence intervals 
(95% CI) and were calculated with VassarStats. The 
distribution of continuous variables were analyzed 
with the Kolmogorov-Smirnov and Shapiro-Wilk tests 
to evaluate their deviation from the normal distribution. 
Continuous were compared using student's t-test or 
Mann-Whitney U test according to their distribution. 
Categorical variables were evaluated using Pearson’s 
chi-squared test.  A multivariable logistic regression 
analysis was undertaken to identify independent 
predictors of infectious and malignant events using 
the Enter method. 
Statistical analyses were performed using the 
Statistical Package for Social Sciences (SPSS) 
software, version 22.0 and the significance level of 
0.05 was considered.  
 
Results 
Study population 
Since January 2000, a total of 387 patients received 
at least 1 month of anti-TNF treatment across the 
different diseases.  Three-hundred and twenty-eight 
patients (84.8%) received only one agent (28.4% 
etanercept, 30.8% adalimumab and 40.9% infliximab), 
59 (15.2%) were treated with a second-line agent 
(23.7% etanercept, 67.8% adalimumab and 8.5% 
infliximab). Four (1.0%) patients received adalimumab 
as a third-line therapy, summing up to 450 treatment 
courses. Data regarding golimumab was excluded 
since only 5 patients were treated with that agent.   
Table 1 summarizes the baseline characteristics of 
the study population as a whole and according to the 
agent used.  
Total treatment time was 1777 patient-years with a 
mean duration of 4.1 years per patient. Almost half of 
the patients treated had at least one comorbidity, the 
most common was hypertension (20.9%), 
dyslipidemia (14.2%) and diabetes (9.3%). 
Furthermore, 15 patients had a secondary IMID (other 
than the one for which anti-TNF was indicated). Eight 
of those cases were psoriasis, 5 ankylosing 
spondylitis, one Chron’s disease and the other 
ulcerative colitis. 
Over half of the patients treated with an anti-TNF for 
any given IMID underwent, at some point, a combined 
therapy either with corticosteroids (22.5%) or 
immunomodulators (59.7%). Triple therapy (anti-TNF 
+ CS + immunomodulator) was administered in 17.3% 
of the patients. Complemental information is provided 
in table 2. 
Regarding the diseases treated with anti-TNFs, most 
patients (183) were treated for Inflammatory bowel 
disease (IBD) followed by patients with Inflammatory 
arthropathies (excluding psoriatic arthritis) and 
Psoriatic diseases each with 102 patients. The anti-
Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: 
Focus on Infections and Malignancy 
23 
TNF used was significantly different concerning the  
disease for which they were prescribed (p<0.001).  
Over half of IBD patients were treated with Infliximab 
and none was treated with Etanercept. Regarding 
psoriatic diseases, on the other hand, 53.7% of 
patients were treated with Etanecept and Infliximab 
accounted only for 10.7% of treatments. Patients with 
inflammatory arthropathies also underwent more 
treatments with Etanercept (45.5%) followed by 
Adalimumab (38%) and Infliximab (16.5%) 
During the observational period, the reason for 
suspension/ switch of an anti-TNF treatment, in most 
patients, was secondary failure of treatment [57/168 
(33.9%)]. Furthermore, adverse events accounted for 
39.3% of suspension/switch with infectious events 
and malignancy accounting, respectively, for 21.2% 
Table 1 - Patient baseline characteristics and treatment duration 
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and 33.3% of the reported adverse events. The 
appearance of psoriatic skin lesions were the adverse 
event responsible for suspension/switch in 8 patients 
(12.1%). On the other hand 13/168 (7.7%) treatments 
were stopped due to an improvement/ remission of the 
disease. Information regarding the reason for 
suspension/switch for each anti-TNF is reported in 
table 3.  
 
Infections 
Vaccination against Influenza and Pneumococcus 
was administered, at least once, during the treatment 
period in 188 and 140 patients respectively. However, 
we did not find a significant reduction in infection rates, 
even when considering only respiratory tract 
infections. 
No HIV infection was detected in the group of patients 
treated with anti-TNFs. On the other hand, one patient 
with chronic HBV and 
another with HCV infection 
were treated with biologics. 
No reactivation occurred 
with any anti-TNF treatment.  
At least one infectious event 
was reported in 171/387 
(44.2%) of the patients and 
multiple infectious events in 
89/387 (23.0 %). A total of 348 
infectious events (79.6% non-serious) were described 
during the observational period resulting in a 19.70 
(95% CI 17.91-21.62) per 100 patient-years incidence 
rate. Most of the infections involved the respiratory 
tract (36.8%), followed by urogenital (21.0%), skin and 
soft tissue (20.7%) and digestive system (12.1%) 
infections. Tables 4 and 5 show the overall rates and 
infectious patterns. 
A total of 71 serious infectious events were diagnosed 
in 55/387 (14.2%) of the patients during the 
observational period accounting for a 4.02 (95% CI 
3.20-5.04) per 100 patient-years incidence rate. As a 
group, digestive system infections accounted for the 
biggest number (22) of serious infections. However, 
the most commonly reported infection was septicemia 
of unknown origin (9) followed by pneumonia (8). 
When considering individual treatments, the IR of 
infectious events in patients treated with etanercept 
was considerably lower, when compared with 
monoclonal antibodies (p= 
0.002), more so when only 
considering serious 
infectious events (p 
Table 2 – Adjunctive therapy and vaccinations 
Table 3 - Reason for anti-TNF suspension / switch 
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<0.002). Furthermore, the infectious patterns vary 
considerably, with a clear predominance for 
respiratory infections in patients treated with 
etanercept and adalimumab whereas patients treated 
with infliximab have a diversified presentation. 
Similarly, the IR of infectious events varies with IMIDs. 
The lowest IR was observed in psoriatic diseases and 
the highest in IBD.  
Bivariate analysis revealed that longer treatment 
duration [OR 1.153 per each year (95% CI 1.072-
1.239), (p<0.001)], female gender [OR 1.503 (95% CI 
1.023-2.209), (p=0.038)] and concomitant 
corticosteroid treatment [OR 1.694 (95% CI 1.097-
2.615), (p=0.017)] increased the risk of infection. 
When considering only serious infectious events, 
bivariate analysis revealed that none of these factors 
had an impact on the risk and only IBD (p<0.001) and 
infliximab (p=0.001) increased the risk, when 
compared with the other indications and treatments, 
respectively.  However, when the multivariate analysis 
was performed none remained statistically significant. 
In fact, when considering the indications separately 
infliximab only increases the risk of serious infections 
(p=0.044) in the group of patients treated for 
inflammatory bowel diseases. Logistic multivariate 
models confirmed that female gender [OR 1.495 (95% 
CI 1.005-2.224), (p=0.047)] and treatment duration 
[OR 1.156 per each year (95% CI 1.074-1.244), 
(p<0.001)] were independent predictors of infections. 
The use of corticosteroid treatment almost reached 
statistical significance [OR 1.532 (95% CI 0.976-
2.405), (p=0.064)].  
 
Tuberculosis 
A total of 332 (85.8%) patients were screened for 
latent TB prior to their first anti-TNF. Screening was 
executed with one or more of the following: TST, chest 
radiography and/or IGRA which were performed in 
278 (71.8%), 275 (71.1%) and 115 (29.7%) patients, 
respectively. LTB screening was positive in 71/332 
(21.4%) patients. Furthermore 86 (22.2%) patients 
underwent prophylactic TB treatment before the start 
of the biologic therapy. Prophylactic treatment was 
Table 4 - Global infectious events’ incidence rates and according to indication 
Table 5 - Infectious events’ incidence rates according to anti-TNF 
Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: 
Focus on Infections and Malignancy 
26 
administered in patients when, despite a negative 
screening, it was deemed clinically appropriate either 
due to a history of contact or past TB.  
During the observational period latent TB was 
detected in 15 patients, 2 (13.3%) of which had a 
history of past TB. Regarding pre-treatment screening 
it was positive in 6/15 (40%) patients that did it. 
Prophylactic treatment was administered to 7/15 
(46.7%) patients. Moreover 5 patients developed 
active TB, which corresponds to an IR of 0.28 (95% CI 
0.12-0.66) per 100 patient-years. Four of the cases 
developed with infliximab [IR 0.62 (95% CI 0.24-1.58) 
per 100 patient-years], the other one, with 
adalimamab [IR 0.17 (95% CI 0.03-0.94) per 100 
patient-years]. Three (60%) of the cases were extra 
pulmonary (miliary TB, tuberculous adenitis and nasal 
tuberculosis). None of them had a past history of TB 
and 4 (80%) of them were screened with negative 
pretreatment screening. 
 
Malignancy 
Among the 387 anti-TNF treated patient, 31 
malignancies were diagnosed during the 
observational period, corresponding to an IR of 1.75 
(95% CI 1.24-2-47) per 100 patient-years. Both solid 
(28) and hematologic (3) malignancies occurred. 
Regarding solid tumors, sites afflicted included 
oropharyngeal (3), colorectal (5), hepatobiliary (1), 
lung (1), breast (4), cervix (1), prostate (1), kidney (1), 
urinary bladder (1), melanoma (1), non-melanoma 
skin (4), brain (2) and endocrine glands (3). One 
specific patient was diagnosed with 2 different 
malignancies during the observational period. 
Furthermore, 5 patients had a history of malignancy 
prior to the anti-TNF therapy. None of them was 
diagnosed with a relapse of their original malignancy / 
developed a new malignancy.  
The IR of malignant events was 1.99 (95% CI 1.21-
3.26) per 100 patient-years in patients with IBD and 
2.39 (95% CI 1.34-4.23) per 100 patient-years in 
patients with psoriatic disease, over two-fold higher 
than in patients with inflammatory arthropathies [0.91 
(95% CI 0.39-2.11) per 100 patient-years]. Regarding 
the anti-TNF agent used during the diagnosis of the 
malignancy, both etanercept [1.92 (95% CI 1.05-3.50) 
per 100 patients-years] and infliximab [2.17 (95% CI 
1.30-3.61) per 100 patients-years] had higher 
incidence rates than adalimumab [1.17 (95% CI 0.57-
2.50) per 100 patients-years]. 
Compared with the remaining patients treated with 
anti-TNFs, the 30 patients that developed a malignant 
tumor were older (mean age: 50.8 vs 42.6 years) at 
the time of starting the biologic treatment [OR 1.048 
per each year (95% CI 1.018-1.080), (p=0.001)], as 
expected from the occurrence of malignancies in the 
general population, and, surprisingly, were 
characterized by a lower prevalence of combined 
therapy [OR 0.382 (95% CI 0.181-0.810, (p=0.010)], 
particularly methotrexate [OR 0.127 (95% CI 0.030-
0.541), (p=0.001)]. Logistic multivariate analysis 
confirmed the increased risk of malignancy with age 
[OR 1.053 per each year (95% CI 1.021-1.085), 
(p=0.001)] and that the decreased risk observed with 
combined therapy was due to methotrexate [OR 0.110 
(95% CI 0.024-0.518), (p=0.005)] and not any 
adjunctive therapy (p=0.833). 
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Discussion 
The aim of this retrospective study was, to evaluate, 
in a real-world setting, the incidence of infectious and 
malignant events in patients, with different IMIDs, 
treated with anti-TNF agents. Information regarding 
infection and cancer patterns as well as potential risk 
factors, with particular focus on the role of the different 
agents and conditions were addressed. 
 
Infections 
Infectious events were reported in a significant 
number of the patients (44.2%). Non-serious 
infections accounted for 79.6% of total infections even 
though the real number must be significantly higher 
due to the underreporting bias inherent to the study 
design. 
Serious infections were experienced by 55 (14.2%) of 
the patients, exceedingly higher than the one found in 
a meta-analysis of randomized control trials (0.61%) 
[Dommasch et al. 2011]. Notwithstanding, similar 
retrospective studies reported considerably lower 
rates than this study [Curtis et al. 2007a; Favalli et al. 
2009; Komano et al. 2011]. The overall IR of serious 
infections was 4.02 (95% CI 3.20-5.04) per 100 
patient-years incidence rate. An similar retrospective 
study reported an analogous IR [Favalli et al. 2009]. 
Nonetheless, several observational studies found, to 
different degrees, higher rates of serious infections 
[Dixon et al. 2006; Komano et al. 2011; Kroesen et al. 
2003; Lichtenstein et al. 2012; Salliot et al. 2007]. 
Some variability may be explained by different 
definitions of serious infections and length of 
observational periods through different studies in 
addition to some underreporting bias. 
When considering overall infections, the most 
common sites involved were the respiratory tract 
followed by urogenital and skin and soft tissue. 
However, when only considering serious infections, 
digestive system infections prevail which is at odds 
with most literature where the patterns are similar to 
the one found overall [Dixon et al. 2006; Germano et 
al. 2014; Komano et al. 2011; Listing et al. 2005; 
Salliot et al. 2007]. Most studies were made in patients 
with RA and spondyloarthropathies, thus these results 
could be explained by the inclusion of patients with 
IBD that may have distinct infectious patterns 
[Ananthakrishnan and McGinley 2013; Deepak et al. 
2013; Nanau et al. 2014]. In this study, like in 
previously published literature, infliximab and 
adalimumab have higher incidence rates of serious 
adverse events, when compared with etanercept 
[Curtis et al. 2007b; Favalli et al. 2009; Girolomoni et 
al. 2012]. Even though others found similar rates 
across the different agents [Dixon et al. 2006; Listing 
et al. 2005]. Previous studies hinted that patients with 
psoriasis have lower rates of serious infectious events 
than those with RA [Moreland et al. 2001; Tyring et al. 
2007]. In fact,  in this study it was observed a higher 
IR in patients with IBD and inflammatory arthropathies 
than in those with psoriatic diseases although it 
cannot be said that it is due to disease since there are 
some prescription bias with a preponderance of 
infliximab in patients with IBD and etanercept in 
psoriatic diseases in addition to dissimilar use of other 
immunosupressants.  
Regarding the risk factors for serious infection, the 
only factors that were statistically increased the risk, 
in the bivariate analysis, were treatment with 
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infliximab and inflammatory bowel disease yet 
multivariate analysis tear down that hypothesis, 
reinforcing the need for clarification of individual risk 
of the different diseases and agents. 
 
Tuberculosis 
The IR of active tuberculosis, in the Portuguese 
general population, was 25 (22-28) per 100.000 
population in 2015 [2015]. Portugal is a country with 
high TB prevalence, nonetheless, an IR approximately 
10-fold higher was found in this group of patients 
treated with anti-TNFs. These numbers should be 
assessed taking into consideration the fact that 
pretreatment screening is largely engaged. In fact 
80% of the patients that had active TB while being 
treated, had a negative pretreatment screening. A 
previous study in Spain reported similar findings and 
hypothesized that the use of other 
immunosuppressants at time of the screening tests 
lead to false negatives results [Jauregui-Amezaga et 
al. 2013]. Moreover, studies in areas with a much 
lower TB incidence also report disproportionate TB 
rates in patients under anti-TNF [Favalli et al. 2009].  
All cases of active TB were diagnosis in patients 
treated with infliximab and adalimumab, hence no 
case of active TB was diagnosed in patients treated 
with etanercept. These findings are in line with larger 
studies that show a significantly higher risk of TB in 
patients treated with monoclonal antibodies [Dixon et 
al. 2010a; Tubach et al. 2009; Wallis et al. 2004]. Sixty 
percent of the tuberculosis diagnosis were 
extrapulmonary which is in accordance with previous 
studies that consistently report extrapulmonary TB in 
over 50% of active TB cases [Alawneh et al. 2014; 
Dixon et al. 2010a; Jauregui-Amezaga et al. 2013]. 
 
Malignancy 
Overall, the IR of malignancy [1.75 (95% CI 1.24-2-
47) per 100 patient-years] was substantially higher 
than the general Portuguese population [0.4419 per 
100 population in 2010] [RORENO 2016]. Previous 
studies have demonstrated similar findings, in 
different populations [Berghen et al. 2015; Chiesa 
Fuxench et al. 2016; Raaschou et al. 2016]. Although 
there is some concern, particularly with lymphomas 
and NMSC, recent data from meta-analyses and 
registers, seem to indicate that treatment with anti-
TNF biologics does not increase the risk of 
malignancy whether in IBD, psoriatic disease or 
inflammatory arthropathies [Askling et al. 2009a; 
Askling et al. 2011; Buchbinder et al. 2015; 
Dommasch et al. 2011; Huang et al. 2011; Kimball et 
al. 2014; Moulis et al. 2012; Pedersen et al. 2010; 
Peyrin–Biroulet et al. 2008; Williams et al. 2014; 
Zhang et al. 2013]. The reported incidence rates, over 
two-fold higher in patients with IBD and psoriatic 
disease when compared with inflammatory 
arthropaties, are reasonable since previous studies 
implicate that disease-related factors, and not the 
treatment, may impact the risk of malignancy 
[Baecklund et al. 2006; Kimball et al. 2014; van Lumig 
et al. 2015]. A meta-analysis of randomized control 
trials described an IR of 1.273 malignancies per 100 
PA in different conditions [Askling et al. 2011]. This 
study results are higher than those of RCTs most likely 
due to the longer observation period. When 
considering the anti-TNFs individually, the same 
meta-analysis reported the opposite finding: the IR of 
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patients treated with adalimumab was higher than 
those treated with etanercept and infliximab (1.423 vs 
1.160 and 1.228 per 100 PA). On the other hand, data 
from clinical trials with adalimumab revealed an IR 
very similar to this study [Burmester et al. 2013]. Data 
regarding malignancy rates is still scant and 
population related factors may have a strong impact, 
especially when considering individual agents with 
different studies reporting discordant results [Askling 
et al. 2009b; Bongartz et al. 2009; Kievit et al. 2011; 
Kimball et al. 2014; Okada and Siegel 2006]. 
Regarding the treatment of patients with a history of 
cancer, no malignancy was reported in the 5 cases 
present. Studies in patients with IBD admit that such 
patients are at increased risk of new or recurrent 
cancers even though anti-TNFs have a minor/ no 
contribution to the increased risk [Axelrad et al. 2016; 
Beaugerie 2013; Dixon et al. 2010b; Poullenot et al. 
2016]. 
Concerning risk factors for malignancy, the present 
study found that age, but not disease duration, 
increased the risk of a malignant event. These results 
suggest a malignancy-protective effect of 
methotrexate. Albeit not being reported previously 
[Krathen et al. 2010; Salliot and van der Heijde 2009], 
theoretically such an effect is possible since, in 
addition to the immunosuppressant effect for which it 
is used in IMIDs, methotrexate is used in the treatment 
of several cancers due to its antineoplastic effect.  
 
The results of this study should take in considerations 
the limitations inherent to the study design. The data 
collected was based on hospital records so 
ascertainment bias, lack of relevant information, 
misclassification, and channeling are probable 
limitations of the study. The sample size and 
observation period must be taken in consideration 
when considering the incidence of rare adverse 
events such as cancer or serious infections, more so 
when breaking down into disease or treatment. 
Furthermore, preceding treatments (other than anti-
TNF) were disregarded although they may have some 
implications. Further limitations specific to the study 
stemmed from the inclusion of different IMIDs. Data 
was collected from patients across 9 different anti-
TNF indications that more than accounting for some 
heterogeneity, prevented us from using classifications 
of disease severity that would be unapproachable. 
Moreover, another simplification was employed by 
encompassing the diseases in 3 groups (IBD, 
Inflammatory arthropathies and Psoriatic diseases). 
Additionally, guidelines regarding anti-TNF treatment 
varied between departments and through the 10 years 
of anti-TNF treatment in the authors’ hospital which 
may account for some variability regarding 
pretreatment screening/ prophylaxis.  
Summing up, anti-TNF biologics are widely used in the 
treatment of IMIDs, particularly in RA, IBD and 
psoriatic diseases. Albeit some safety concerns, they 
are a powerful therapeutic weapon that allow the 
control of, above all, severe presentations of this 
conditions. 
Physicians, never the less, should be aware that anti-
TNFs may increase the risk of infections that could 
have severe consequences. On the subject of TB, 
despite active screening, it continues to be an 
important problem in patients treated with anti-TNF 
biologics, especially in parts of the world with a high 
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background TB prevalence. Current evidence is not 
robust enough to exclude anti-TNFs from having an 
impact in the overall risk of malignancy thus tight 
surveillance should be employed in everyday practice.  
Caution in generalizing data from the literature should 
be employed, since the safety profile of these agents 
may be substantially altered depending on the 
disease for which they are used. Hence, future 
studies/ registries should be developed, evaluating 
longer follow-up durations, ideally matching anti-TNF 
naïve populations, in order to further elucidate the risk 
of individual anti-TNF treatments in the different 
IMIDs.  
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CONCLUSÃO 
O objetivo deste projeto foi avaliar a incidência de infeções e neoplasias em doentes com 
diferentes doenças inflamatórias imunomediadas tratados com agentes anti-TNF, em 
condições de prática clínica. Foram ainda abordados os tipos de infeções e neoplasias, 
potenciais fatores de risco, com particular destaque para o papel dos diferentes agentes e 
patologias. 
Neste estudo foi avaliada uma amostra de tamanho significativo: 387 doentes (450 
tratamentos anti-TNF diferentes) com um tempo total de tratamento de 1777 doentes-ano. 
Ao longo deste período observacional foram registadas infeções em 44.2% e infeções 
graves em 14.2% dos doentes correspondendo a taxas de incidência de 19.70 (IC 95% 
17.91-21.62) e 4.02 (IC 95% 3.20-5.04) por 100 doentes-ano, respetivamente. Estas taxas 
estão muito provavelmente subvalorizadas.  
Está preconizada a realização de um rastreio pré-tratamento da tuberculose latente, VIH, 
hepatite B e C, entre outros, de modo a que as medidas necessárias possam ser tomadas.  
Relativamente à infeção da hepatite B, é aceite que as terapêuticas anti-TNF têm risco de 
reativação da doença crónica. Contudo, no que toca aos doentes com serologias 
compatíveis com infeção passada, o risco conferido pelas terapêuticas anti-TNF não é 
claro. Nesta série de doentes, observaram-se 26 casos compatíveis com infeção passada 
sendo que nenhuma reativação foi registada. Outras séries admitem que a reativação é 
possível neste grupo de doentes, apesar de ser muito menos comum do que em doentes 
com infeção crónica pelo vírus da hepatite B. Por outro lado, apesar de existir um protocolo 
de rastreio da hepatite B no CHP este, frequentemente, não é cumprido (75% dos doentes 
rastreados). 
A tuberculose é das principais preocupações em doentes expostos a agentes anti-TNF pois 
estes têm maior risco de reativação da doença latente. Para além disso, a tuberculose é 
mais frequentemente atípica, extrapulmonar ou disseminada estando presente mesmo em 
doentes com rastreio da tuberculose latente negativo. Portugal é um país com alta 
prevalência de TB, no entanto, a taxa de incidência deste estudo [0.28 (IC 95% 0.12-0.66) 
por 100 doentes-ano] é aproximadamente 10 vezes superior à da população portuguesa. 
Estes números devem ser avaliados tendo em conta o facto de que na maioria destes 
doentes (86%) foi realizado um rastreio pré-tratamento. Este estudo mostra resultados 
concordantes com a literatura: formas extrapulmonares mais frequentes (60%), maior risco 
com anticorpos monoclonais (100%) e casos em doentes com rastreio pré-tratamento 
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negativo (80%). 
Relativamente às neoplasias, foram registados 31 casos [taxa de incidência de 1.75 (IC 
95% 1.24-2.47) por 100 doentes-ano]. Em relação ao tratamento com agentes anti-TNF em 
doentes com antecedentes de neoplasias, foram detetados 5 casos neste estudo, onde 
nenhuma recidiva ou neoplasia de novo foi detetada. Vários estudos conjeturam que o risco 
de recidiva ou aparecimento de neoplasias está mais relacionado com a atividade 
inflamatória destas patologias e que os anti-TNF tem um contribuição reduzida ou nula para 
o aumento do risco. Algo que não estava descrito anteriormente na literatura e que foi 
evidente neste grupo de doentes, foi o facto da terapia combinada com metotrexato parecer 
reduzir o risco de neoplasia. Tal pode ser explicado pelo seu efeito antineoplásico, motivo 
pelo qual é utilizado no tratamento de diversas neoplasias. 
As taxas de incidência dos eventos infeciosos e neoplásicos são similares às reportadas 
em estudos com desenho semelhante. A importância destes acontecimentos é evidente 
quando se verifica que a principal causa para a interrupção das terapêuticas anti-TNF são 
os efeitos adversos e mais de metade destes são neoplasias ou infeções. 
Doenças caracterizadas por inflamação crónica têm um risco inerente de infeção e 
neoplasias por várias razões relacionadas com a doença e não apenas pelo tratamento. 
Este estudo mostrou que os doentes tratados com anticorpos monoclonais têm taxas de 
incidência de infeções graves superiores aos tratados com etanercept, como já publicado 
anteriormente. Algo semelhante é, contudo, verificado quando as taxas de incidência são 
comparadas por indicação. Os doentes tratados por doença psoriática têm menor taxa de 
incidência de infeções graves quando comparados com as restantes indicações. 
Existe uma variabilidade significativa na taxa de incidência de infeções e doenças malignas 
de acordo com as diferentes indicações e agentes. A generalização de dados da literatura 
sobre o uso de um agente numa determinada patologia pode ser incorreta. Mais estudos 
são necessários para esclarecer aspetos relacionados com a segurança individual dos 
agentes anti-TNF e clarificar o seu impacto nas diferentes doenças inflamatórias 
imunomediadas. 
Em suma, os tratamentos anti-TNF são relativamente seguros se as precauções 
apropriadas forem tomadas. Para evitar os efeitos adversos o médico deve estar ciente 
das complicações possíveis e das recomendações de rastreio e follow-up dos doentes 
tratados com estes agentes.  
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Abstract 
Introduction: Immune-mediated inflammatory diseases are estimated to affect 5% to 7% 
of the population in Western countries. One of the emerging therapies against this diseases 
are biologics. This biologics are use in a great number of patients and a diverse group of 
pathologies and there have always been safety concerns regarding these drugs. Anti-tumor 
necrosis factor has significantly changed the treatment and outcome of several 
inflammatory diseases as Rheumatoid Arthritis, inflammatory bowel disease and Psoriasis 
however concerns regarding the safety and efficacy of these agents have been raised. 
Objectives: In this study we intend to investigate the incidence, as well as the prevalence 
of infections and malignancy in patients with IMIDs treated with anti-TNF as currently there 
is no information regarding anti-TNF therapies and its adverse effects in Portugal. 
Materials and Methods: This retrospective observational study will be conducted in CHP. 
The patients that received anti-TNF agents for the treatment of IMIDs will be included.  
  
Resumo 
Introdução: Estima-se que no seu conjunto as doenças inflamatórias imunomediadas 
afectem 5 a 7% da população dos países ocidentais. Uma das terapêuticas emergentes 
usadas contra este grupo de doenças são os agentes biológicos. Estes fármacos são 
usados num grande número de doentes bem como num diverso grupo de patologias e 
sempre existiram preocupações com a segurança destes agentes. Os biológicos anti-TNF 
alteraram de um modo significativo o tratamento e prognóstico de doenças como a Artrite 
Reumatoide, doença inflamatória intestinal e psoríase contudo continuam a existir 
preocupações com a segurança e eficácia destes agentes. 
Objetivos: Neste estudo pretende-se investigar a incidência, bem como a prevalência de 
infeções e neoplasias em pacientes com doenças inflamatórias imunomediadas tratados 
com biológicos anti-TNF visto que atualmente não há qualquer informação relativamente a 
terapêuticas anti-TNF e os seus efeitos adversos em Portugal. 
Materiais e Métodos: Este estudo observacional retrospetivo irá ser conduzido no CHP. 
Serão incluídos os adultos que receberam biológicos anti-TNF para o tratamento de uma 
doença inflamatória imunomediada. 
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Introduction 
Immune-mediated inflammatory diseases (IMIDs) are defined as a group of chronic and 
highly incapacitating conditions that are not clinically related but share an immune 
dysregulation caused or accompanied by acute or chronic inflammation [1,2]. They are 
estimated to affect 5% to 7% of the population in Western countries [3] and their treatment 
focuses on the rapid control of inflammation, prevention of tissue damage, with the goal of 
long-term remission of the disease, thus improving quality of life. The primary therapeutic 
assets available are corticosteroids, immunosuppressants, and biologic agents, especially 
those targeting tumor necrosis factor (TNF) [3]. 
Anti-tumor necrosis factor (anti-TNF) therapies were first introduced into clinical practice in 
1998 for the treatment of inflammatory bowel diseases and Rheumatoid Arthritis. 
Thenceforth they have significantly changed the treatment and outcome of several 
inflammatory diseases [4]. It is generally known that patients with chronic inflammatory 
diseases have a higher risk of infection and malignancy for several disease-related reasons 
[3,5,6]. Presently there are some concerns regarding the safety and efficacy of these agents 
although the data concerning this subject is getting more robust amongst more than a 
decade of treatment for diverse diseases. Even so, different studies have had inconsistent 
results concerning the safety profile. Some reports have revealed an increase in the overall 
serious infection rate [7,8], while others stated that there is no significant increase in serious 
infections [9-11]. The increased risk of developing tuberculosis has been of special concern 
since TNF has an important biological role in the formation of granuloma and containment 
of the disease [12]. In regard to malignancy, earlier studies reported increased risk of 
lymphoma  and malignancies overall [13,14]. However more recent studies do not associate 
anti-TNF biologics with an increased risk in solid or hematologic malignancies [9,10,15-21] 
with the exception of melanoma and non-melanoma skin cancer (NMSC) [22,23]. 
The aim of this research project is to survey information available in Centro Hospitalar do 
Porto (CHP) regarding anti-TNF therapies and focusing on infections and malignancy, as 
concerning and life threatening adverse effects, in CHP’s patients treated in the following 
diseases: Psoriasis (Ps) and Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ankylosing 
Spondylitis (AS), Juvenile Idiopathic Arthritis (JIA) and inflammatory bowel diseases (IBD), 
such as Crohn’s Disease (CD) and Ulcerative Colitis (UC).  
The investigators are aware that as this study is observational, retrospective as well as 
lacking a control population and with a limited number of patients no information will be 
produced regarding the relative risk of intercurrences. Nonetheless our objective is to 
compare our data with previously published studies thus assessing our reality. 
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Clinical problems 
There is no information regarding patients with IMIDs treated with anti-TNF therapies in 
Portugal. This biologics are use in a great number of patients and a diverse group of 
pathologies and there have always been safety concerns regarding these drugs. 
Research questions 
What is our reality? 
What is the incidence of infection and malignancy in our patients treated with anti-TNF? 
What is the prevalence of infections and malignancy in this group of patients? 
Research goals 
In this study we intend to investigate the incidence, as well as the prevalence of infections 
and malignancy in patients with IMIDs treated with anti-TNF. 
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Contributors 
Institutions, Departments and Services 
 Centro Hospitalar do Porto (CHP). 
o Hospital de Santo António (HSA). 
 Departamento de Medicina (DM). 
 Serviço de Dermatologia (SD), Serviço de Gastrenterologia (SG) e Unidade de 
Imunologia Clínica (UIC). 
Research Team 
Constitution  
Student 
Rui Pereira: medical student, Disciplina de Iniciação à Investigação Clínica (DIIC), 
Mestrado Integrado em Medicina (MIM), ICBAS/UP 
Other researchers  
 Paula Lago, M.D.: Serviço de Gastrentologia, Centro Hospitalar do Porto. 
 Raquel Faria, M.D.: Unidade de Imunologia Clínica, Centro Hospitalar do Porto. 
Tutor 
 Tiago Torres, M.D., Ph.D.: Serviço de Dermatologia, Centro Hospitalar do Porto, 
Unit for Multidisciplinary Research in Biomedicine – ICBAS/UP, Dermatology Research 
Unit, Centro Hospitalar do Porto. 
DIIC Supervisor 
 Margarida Lima: M.D., Ph.D., invited professor, ICBAS/UP;  
Roles and responsibilities 
 The conception and development of the proposal and the project’s execution are the 
responsibility of the student; 
 The Tutor will chaperon the student in the development of the proposal and in the 
project’s execution and the analysis and interpretation of the results. 
 The Supervisor will manage all the project’s phases from its conception, execution, 
data analysis to the presentation of the results. 
Time allocated to the project 
First and last 
name 
Function % Time allocated to the 
project 
N of 
months 
People * 
Month 
Rui Pereira Student 10 22 2,20 
Tiago Torres Tutor 2,5 22 0,55 
Paula Lago Researcher 2,5 22 0,55 
Raquel Faira Researcher 2,5 22 0,55 
Margarida Lima Supervisor 2,5 22 0,55 
Total 4,40 
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Conditions and motivations for the development of the project 
Installed capacities and available resources 
For the development of this project it will be necessary access to clinical records (material 
and digital) so a space with capacity for the analysis of this material will be required.  
Investigation team merit 
Tiago Torres, Paula Lago and Raquel Faria have both clinical and investigational 
experience in the project’s area. 
Personal motivations for the development of the project 
The personal motivations in integrating a team for the development of a project start from 
the lack of opportunities in our degree to accomplish and learn the processes of a clinical 
investigation. As to the area, Dermatology was chosen because in my classes with Dr. Tiago 
Torres I got to know a little about psoriasis and understood that there was a lot of 
investigation in that area and that it was a lot more extensive. 
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Methodology  
Literature review criteria 
For the literature review B-On was employed as a means to access the articles researched 
was in Medline via PubMed. English articles were searched with the following keywords: 
safety, adverse event, immune-mediated inflammatory diseases, anti-TNF, psoriasis, 
inflammatory bowel disease, rheumatoid arthritis, infection, malignancy, ankylosing 
spondylitis, juvenile idiopathic arthritis, Crohn’s disease and ulcerative colitis. The search 
results were then supplemented by including documents suggested by authors’ experience. 
Project design 
Project type 
Clinical research, institutional, analytical observational and longitudinal (retrospective), 
cohort study with a clinical scope. 
Universe, population and sample 
Universe: 
Adult patients treated with anti-TNF. 
Population:  
Adult patients treated with anti-TNF in Dermatology, Gastroenterology or Clinical 
Immunology in CHP. 
Sample:  
Size intended for the sample: 400 patients (all the adult patients treated with anti-TNF in the 
above mentioned medical departments).  
Participant selection 
Elegebility criteria 
Inclusion criteria  
Adult patients treated with anti-TNF therapeutics in Dermatology, Gastroenterology or 
Clinical Immunology in CHP since January 2000 until February 2015. 
Exclusion criteria 
Patients with missing information will be excluded. 
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Project plan 
Project related tasks 
Task list: 
During the project’s execution the following tasks are foreseen: 
Task 1: Participant selection 
Duration: 1 month 
Foreseen dates for the beginning and 
conclusion: 
05/01/2015 – 30/01/2015 
Institutions, Departments and Services: CHP – HSA – DM: SD, SG and UIC 
Objectives: Select participants for data recovery. 
Description: Cases will be selected form the different 
departments with regard to the 
inclusion/exclusion criteria. 
Involved investigators: Dr. Tiago Torres, Dr. Paula Lago and Dr. 
Raquel Faria 
Investigators functions and 
responsibilities: 
Dr. Tiago Torres is responsible for the 
selection in Dermatology, Dr. Paula Lago 
in Gastroenterology and Dr. Raquel Faria 
in Immunology. 
 
Task 2: Data recovery 
Duration: 4 months 
Foreseen dates for the beginning and 
conclusion: 
16/02/2015– 26/06/2015 
Institutions, Departments and Services: CHP – HSA – DM: SD, SG and UIC 
Objectives: Collect the data for the study. 
Description: Fill the data recovery sheet with the 
available information in the physical and 
informatics process for every selected 
case. 
Involved investigators: Dr. Tiago Torres and Rui Pereira 
Investigators functions and 
responsibilities: 
Dr. Tiago Torres will overlook Rui Pereira 
in the data recovery. 
 
Task 3: Database construction 
Duration: 1 month 
Foreseen dates for the beginning and 
conclusion: 
29/06/2015– 31/07/2015 
Institutions, Departments and Services: CHP – HSA – DM: SD, SG and UIC 
Objectives: Construction of the database for the data 
analysis.  
Description: The data collected will be inputted in a 
spreadsheet in SPSS for posterior data 
analysis, 
Involved investigators: Rui Pereira 
Investigators functions and 
responsibilities: 
Rui Pereira is solely responsible for this 
task. 
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Task 4: Data analysis 
Duration: 1 month 
Foreseen dates for the beginning and 
conclusion: 
01/09/2015– 30/09/2015 
Institutions, Departments and Services: CHP – HSA – DM: SD, SG and UIC 
Objectives: Analyze the recovered data. 
Description: The data obtained will be analyzed with 
SPSS and the relevant data will be 
selected for presentation. 
Involved investigators: Rui Pereira 
Investigators functions and 
responsibilities: 
Rui Pereira with the help of Professor 
Isabel Fonseca will analyze the data. 
 
Task 5: Review article 
Duration: 5 months 
Foreseen dates for the beginning and 
conclusion: 
03/11/2014– 27/03/2015 
Institutions, Departments and Services: CHP – HSA – DM: SD, SG and UIC 
Objectives: Publishing of a Review article. 
Description: A bibliographic review will be 
accomplished and a review article for 
publishing structured. 
Involved investigators: Dr. Tiago Torres and Rui Pereira 
Investigators functions and 
responsibilities: 
Rui Pereira is responsible for the 
development of the article. Dr. Tiago 
Torres will oversee and audit the article. 
 
Task 6: Original article 
Duration: 3 months 
Foreseen dates for the beginning and 
conclusion: 
05/10/2015– 01/01/2016 
Institutions, Departments and Services: CHP – HSA – DM: SD, SG and UIC 
Objectives: Publishing of an Original article. 
Description: The results will be constructed into an 
original article for publishing. 
Involved investigators: Dr. Tiago Torres and Rui Pereira 
Investigators functions and 
responsibilities: 
Rui Pereira is responsible for the 
development of the article. Dr. Tiago 
Torres will oversee and audit the article. 
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Task 7: Oral presentation of the project 
Duration: 2 weeks 
Foreseen dates for the beginning and 
conclusion: 
08/06/2015– 26/06/2015 
Institutions, Departments and Services: CHP – HSA – DM: SD, SG and UIC 
Objectives: Preparation for the JIIC. 
Description: Preparation of the presentation of the 
project for the JIIC. 
Involved investigators: Rui Pereira 
Investigators functions and 
responsibilities: 
Rui Pereira is responsible for the 
presentation of the project with the help of 
Dr. Margarida Lima. 
 
Task 8: Oral presentation of the results 
Duration: 2 weeks 
Foreseen dates for the beginning and 
conclusion: 
06/06/2016– 24/06/2016 
Institutions, Departments and Services: CHP – HSA – DM: SD, SG and UIC 
Objectives: Preparation for the JIIC. 
Description: Preparation of the presentation of the 
results for the JIIC. 
Involved investigators: Rui Pereira 
Investigators functions and 
responsibilities: 
Rui Pereira is responsible for the 
presentation of the results with the help of 
Dr. Margarida Lima. 
 
Material and methods 
Data recovery instruments 
For this project a formulary, present in the addendum list, was created for clinical data 
recovery. 
Data analysis  
The data will be analyzed with descriptive statistics to present the characteristics of the 
population as well as the incidence of adverse events and the groups with higher risk. With 
statistical inference we will compare the results of our study with previously published 
studies accounting for the sociodemographic and clinical characteristics of the studied 
populations. 
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Scheduling  
Date of beginning and conclusion (duration in months)  
Global: September of 2014 until July of 2016 (22 months) 
Planning: September of 2014 until July of 2015 (11 months)  
Execution: September of 2014 until July of 2016 (11 months) 
Chronogram 
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Production indicators 
Oral communications and posters 
 Oral presentation of the project proposal in the JIIC (June 2015) 
 Oral presentation of the results in the JIIC (June 2016) 
Written projects 
 Academic research project proposal (February 2015) 
 Review article for publication in a national or international medical magazine with 
scientific arbitration (2015) 
 Original article for publication in a national or international medical magazine with 
scientific arbitration (2015) 
 MIM Thesis (July 2016) 
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 ETHICAL QUESTIONS 
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Other questions with ethical implications 
Privacy and anonymization 
A data crossing key will be implemented to keep apart the data from the patient’s 
identification. 
Other aspects 
In regard to standing CHP regulation the data from clinical processes will be consulted 
under supervision of the tutor in a suitable place inside CHP installations. 
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FINANCIAL PLAN 
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Budget 
 
 Estimated costs (€) 
Administrative material (printing, paper, etc.) *00,00 
Publication costs for a review article and an article presenting the 
results 
750,00 
Poster printing for presentation of the results  *00,00 
Jornadas de Iniciação à Investigação Clínica (JIIC) Organization 50,00 
TOTAL 800,00 
*Printing available through ICBAS/UP  
 
Funding  
This project will be funded by ICBAS/UP, through a grant reserved for DIIC. 
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Abbreviations 
IMID, Immune-mediated inflammatory diseases 
TNF, Tumor necrosis factor 
Ps, Psoriasis 
PsA, Psoriatic arthritis 
RA, Rheumatoid arthritis 
AS, Ankylosing spondylitis 
CD, Crohn’s disease 
UC, Ulcerative colitis  
 
Acronyms 
CHP, Centro Hospitalar do Porto 
DIIC, Disciplina de Iniciação à Investigação Clínica. 
DM, Departamento de Medicina. 
HSA, Hospital de Santo António. 
SD, Serviço de Dermatologia 
SG, Serviço de Gastrenterologia 
UIC, Unidade de Imunologia Clínica 
ICBAS, Instituto de Ciências Biomédicas Abel Salazar. 
JIIC, Jornadas de Iniciação à Investigação Clínica. 
MIM, Mestrado Integrado em Medicina. 
UP, Universidade do Porto. 
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Addendum list 
 
 Formulário de recolha de dados 
 Lista de documentos para trabalhos académicos de investigação (que conferem grau) 
 Folha de rosto do estudo de investigação 
 Pedidos de autorização (Presidente do Conselho de Administração do CHP, Presidente 
da Comissão de Ética para a Saúde do CHP, Diretora do Departamento de Ensino, 
Formação e Investigação do CHP). 
 Termos de responsabilidade (Aluno, Orientador, Regente da DIIC) 
 Autorizações locais (Departamentos e Serviços do CHP envolvidos no projeto) 
 Carta dirigida ao Presidente da Comissão de Ética para a Saúde do CHP a solicitar 
dispensa de consentimento informado  
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Formulário de recolha de dados 
Trabalho académico de investigação: 
Safety of anti-TNF therapies in immune-mediated inflammatory diseases: focus on 
infections and malignancy 
Aluno da DIIC do curso de MIM do ICBAS/UP e do CHP:  
Rui Pereira 
 
INFORMAÇÃO GERAL 
Género M □ F □ Data de Nascimento _____ /_____ /_____ 
Antecedentes HBV □  HCV □ HIV □ Tuberculose □  Neoplasias □ Outros □ 
Quais 
_____________________________________________________________________ 
Rastreio tuberculose Mantoux □ + □ - □ Rx □ + □ - □ IGRA □ + □ - □  
Quimioprofilaxia 
____________________________________________________________ 
Comorbilidades  
Quais ________________________________________________________ 
 
Tabagismo S □ N □ Álcool S □ N □ 
 
INFORMAÇÃO DA DOENÇA 
Doença Artrite Reumatoide □ Espondilite anquilosante □ 
Espondiloartropatia não radiológica □ Artrite idiopática juvenil □ 
IBDU □ Doença de Crohn □ Colite Ulcerosa □ Psoriase □ Artrite Psoriática □ 
Data de diagnóstico _____ /_____ /_____ 
 
TERAPÊUTICA 
Infliximab □ Adalimumab □ Etanercept □ Certolizumab □ Golimumab □ 
Data (início) _____ /_____ /_____ Data (fim) _____ /_____ /_____ 
Dose média _____________________  
Frequência __________________________________ 
Razão da suspensão  
__________________________________________________________ 
Monoterapia □ Terapêutica adjuvante □ 
Imunomoduladores □  
Quais __________________________________________________ 
Data (início) _____ /_____ /_____ Data (fim) _____ /_____ /_____ 
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Razão da suspensão ______________________________ Dose média ______________ 
Corticóides Sistémicos □ Quais _____________________________________________ 
Data (início) _____ /_____ /_____ Data (fim) _____ /_____ /_____ 
Razão da suspensão ______________________________ Dose média ______________ 
 
INTERCORRÊNCIAS 
Vacinação Influenza □  Pneumocócica □  
Outras ____________________________________ 
Rastreio anual TB □ Mantoux □ + □ - □ Rx □ + □ - □ IGRA □ + □ - □ 
Intervenções cirúrgicas Quais (datas) 
____________________________________________ 
______________________________________________________________________ 
Complicações 
Infecção □  Infecção Severa □  Neoplasias □   
Outras _________________________________ 
Data _____ /_____ /_____  
Órgão ________________________________________________ 
Agente causal 
 ________________________________________________________________ 
Consequências Int transitória □ Int definitiva □ Switch do anti-TNF □ Morte □  
Outras ________________________________________ 
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Lista de documentos para  
TRABALHOS ACADÉMICOS DE INVESTIGAÇÃO (que conferem grau) 
 
 
 
Data de entrega 
(ou NA, não 
aplicável) 
Secretariado 
(Assinatura) 
 
Documentos comprovativos 
 
Inscrição em Licenciatura, Mestrado ou Doutoramento NA  
 
Cartas do Aluno, a solicitar autorização institucional 
Presidente do Conselho de Administração X  
Presidente da CES X  
Diretor do DEFI X  
Termos de responsabilidade de Alunos e Orientadores 
Aluno X  
Orientador do Projeto X  
Supervisor do Projeto, Docente responsável pela DIIC X  
Termos de autorização local (no CHP) 
Responsáveis por Unidades / Gabinetes / Setores* NA  
Diretores de Serviço X  
Diretores / Conselhos de Gestão de Departamentos X  
 
Proposta 
 
Folha de Rosto do Estudo de Investigação (modelo 
próprio) 
X  
Proposta de Trabalho Académico de Investigação X  
 
Anexos 
 
Curriculum Vitae do Aluno  NA  
Termo de Consentimento Informado NA  
Folheto com informação para dar aos Participantes NA  
Carta a solicitar dispensa de Consentimento 
Informado* 
X  
Inquéritos / questionários ou guiões de entrevistas* NA  
Formulário para recolha de dados dos processos 
clínicos* 
X  
Outros documentos* NA  
 
* Se aplicável. 
SECRETARIADO: Data de conclusão da entrega de documentação 
 
 
        Data       Assinatura 
___/___/_____   _________________________ 
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Folha de rosto do estudo de investigação 
 
TÍTULO 
SAFETY OF ANTI-TNF THERAPIES IN IMMUNE-MEDIATED INFLAMMATORY 
DISEASES: FOCUS ON INFECTIONS AND MALIGNANCY 
 
CLASSIFICAÇÃO 
Trabalho Académico de Investigação ☑ (Mestrado Integrado em Medicina) 
Projecto de Investigação  ☑  
Ensaio Clínico  □  Medicamentos □  Dispositivos médicos □ 
Outro □     Qual?      
VERSÃO 
Novo  ☑   Modificação / Adenda □  Prolongamento  □  
CALENDARIZAÇÃO 
Data início: Maio 2015 Data conclusão: Junho 2016 Prazo a cumprir: Junho 
2016 
ALUNOS E ORIENTADORES 
Aluno  
Rui Pereira, ICBAS/UP, 5º ano do MIM, ppereira.rui@gmail.com, 916370627 
 
Orientador do projeto  
Tiago Torres, médico, especialista em Dermatologia e Venereologia assistente hospitalar, 
Serviço de Dermatologia do CHP; Doutorado em Ciências Médicas, ICBAS/UP, 
tiagotorres2002@hotmail.com 
 
Supervisor do projeto / Responsável pela DIIC 
Margarida Lima, médica, especialista em Imunohemoterapia assistente hospitalar 
graduada, consultora, Serviço de Hematologia Clínica do CHP; Doutorada em Ciências 
Médicas, ICBAS/UP, margaridalima@chporto.min-saude.pt 
 
OUTROS INVESTIGADORES 
Investigadores  
Paula Lago, especialista em Gastrenterologia assistente hospitalar graduada, Serviço de 
Gastrenterologia do CHP 
Raquel Faria, especialista em Medicina Interna, assistente hospitalar, Serviço de 
Medicina do CHP;  
 
PROMOTOR O próprio ☑ 
INSTITUIÇÕES E SERVIÇOS 
 Unidades, Departamentos e Serviço do CHP  
Departamento de Medicina: Serviço de Dermatologia (Proponente), Serviço de 
Gastrenterologia e Unidade de Imunologia Clínica 
 
Outras Instituições intervenientes  
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CARATERÍSTICAS do estudo (Assinale as opções corretas) 
Alvo do estudo     Países / Instituições envolvidos 
Animais □  Humanos ☑   Multinacional  □   Nacional  ☑  
Multicêntrico  □  Institucional ☑  
Natureza do estudo     Caraterísticas do estudo (desenho) 
Clínico  ☑  Terapêutico ☑  Descritivo ☑  Analítico ☑  
Epidemiológico □  Laboratorial □ Observacional ☑  Experimental □  
       Transversal ☑  Longitudinal  □ 
       (Retrospetivo ☑  Prospetivo  □) 
Estudo de síntese  □ (Revisão narrativa □  Revisão sistemática □ Revisão 
sistemática meta-análise □) 
Participantes  
Existência de grupo controlo: Não ☑  Sim □  
Seleção dos Participantes: Aleatória □   Não aleatória ☑  
Estudos observacionais:   
Tipo: Caso □  Série de casos ☑ Casos-controlos  □      Coortes  □   
Outro □ 
Estudos experimentais: 
Conhecimento: Aberto □        Cego  □         (Duplamente cego  □ ) 
Ensaios Clínicos: Fase I □       Fase II □         Fase III □      Fase IV □  
Outros aspetos relevantes para a apreciação do estudo: 
Participação de grupos vulneráveis Não ☑  Sim □   
Convocação de doentes / participantes  Não ☑  Sim □    
Consentimento informado Não ☑  Sim □ (Carta a solicitar dispensa: 
Não □ Sim ☑)      
Inquéritos / questionários  Não ☑  Sim □   
Entrevistas  Não ☑  Sim □ 
Colheita de produtos biológicos Não ☑  Sim □  
Armazenamento de produtos biológicos Não ☑  Sim □  
Criação de bancos de produtos biológicos  Não ☑  Sim □  
Realização de exames / análises Não ☑  Sim □   
Realização de estudos genéticos Não ☑  Sim □  
Recolha de dados Não □  Sim ☑ (Dados: clínicos ☑  
laboratoriais: analíticos ☑  / imagem ☑ ) 
Criação de bases de dados Não □  Sim ☑ (Não anonimizadas □  
Anonimizadas ☑ ) - Ficheiro de Excel 
Saída para outras instituições Não ☑  Sim □   
 
ORÇAMENTO E FINANCIAMENTO 
Orçamento total: 800 Euros Contrato financeiro em anexo: Não ☑    Sim □ 
Financiamento: Interno (CHP): 0 Euros  Externo (Outros): 800 Euros 
Entidades financiadoras: Bolsa do ICBAS para os alunos da DIIC 
INDICADORES  
 Dissertação MIM ☑   
 
Data: Abril 2015    Assinatura do proponente (Aluno):  
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Pedidos de autorização institucional 
Trabalho académico de investigação: 
Safety of anti-TNF therapies in immune-mediated inflammatory diseases: focus on 
infections and malignancy 
Aluno da DIIC do curso de MIM do ICBAS/UP e do CHP:  
Rui Pereira 
Presidente do Conselho de Administração do CHP 
Exmo. Senhor Presidente do Conselho de Administração do CHP 
Rui Miguel Pedrosa Pereira, na qualidade de Aluno, vem por este meio, solicitar a Vossa 
Exa. autorização para realizar no Centro Hospitalar do Porto o Estudo de Investigação 
acima mencionado, de acordo com o programa de trabalhos e os meios apresentados. 
        Data       Assinatura 
___/___/_____   _________________________ 
 
Presidente da Comissão de Ética para a Saúde do CHP 
Exma. Senhora Presidente da Comissão de Ética para a Saúde do CHP 
Rui Miguel Pedrosa Pereira, na qualidade de Aluno, vem por este meio, solicitar a Vossa 
Exa. autorização para realizar no Centro Hospitalar do Porto o Estudo de Investigação 
acima mencionado, de acordo com o programa de trabalhos e os meios apresentados. 
        Data       Assinatura 
___/___/_____   _________________________ 
 
Diretora do Departamento de Ensino, Formação e Investigação do CHP 
Exma. Senhora Diretora do Departamento de Ensino, Formação e Investigação do CHP 
Rui Miguel Pedrosa Pereira, na qualidade de Aluno, vem por este meio, solicitar a Vossa 
Exa. autorização para realizar no Centro Hospitalar do Porto o Estudo de Investigação 
acima mencionado, de acordo com o programa de trabalhos e os meios apresentados. 
        Data       Assinatura 
___/___/_____   _________________________ 
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Termos de responsabilidade 
Trabalho académico de investigação: 
Safety of anti-TNF therapies in immune-mediated inflammatory diseases: focus on 
infections and malignancy 
Aluno da DIIC do curso de MIM do ICBAS/UP e do CHP:  
Rui Pereira 
Aluno 
Na qualidade de Aluno, comprometo-me a executar o estudo de investigação acima 
mencionado, de acordo com o programa de trabalhos e os meios apresentados, 
respeitando os princípios éticos e deontológicos e as normas internas da instituição. 
Aluno       Data   Assinatura 
Rui Pereira      ___/___/___ _________________ 
Orientador do projeto 
Na qualidade de Orientador, solicito autorização do Conselho de Administração para que 
o Aluno acima referido possa desenvolver no CHP o seu estudo de investigação. Informo 
que me comprometo a prestar a orientação necessária para uma boa execução do mesmo 
e a acompanhar o Aluno nas diferentes fases da sua realização, de acordo com o programa 
de trabalhos e meios apresentados, bem como por zelar pelo respeito dos princípios éticos 
e deontológicos e pelo cumprimento das normas internas da instituição. 
Nome       Data   Assinatura 
Tiago Torres      ___/___/___
 ____________________ 
Instituição   Departamento    Serviço / Setor 
CHP    Medicina   Dermatologia    
Supervisor do projeto / Responsável pela DIIC 
Na qualidade de Docente Responsável pela DIIC / Supervisor do Aluno no CHP, 
comprometo-me a prestar a orientação necessária para uma boa execução do estudo de 
investigação, de acordo com o programa de trabalhos e meios apresentados. Mais declaro 
que acompanharei o Aluno, responsabilizando-me por supervisionar a execução do 
trabalho no CHP, bem como por zelar pelo respeito dos princípios éticos e deontológicos e 
pelo cumprimento das normas internas da instituição. 
Nome     Data    Assinatura 
Margarida Lima   ___/___/___   __________________ 
Docente responsável pela DIIC 
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Termos de autorização local 
Estudo de investigação: 
Safety of anti-TNF therapies in immune-mediated inflammatory diseases: focus on 
infections and malignancy 
Aluno da DIIC do curso de MIM do ICBAS/UP e do CHP:  
Rui Pereira 
Diretores de Serviço 
Na qualidade de Diretor de Serviço, declaro que autorizo a execução do estudo de 
investigação acima mencionado e comprometo-me a prestar as condições necessárias 
para a boa execução do mesmo, de acordo com o programa de trabalhos e os meios 
apresentados. 
Serviço   Nome do Diretor  Data   Assinatura 
Dermatologia               Manuela Selores  ___/___/___ _______________ 
Gastrenterologia             Isabel Pedroto  ___/___/___ _______________ 
Unidade de Imunologia Clínica Carlos Vasconcelos ___/___/___ _______________ 
Diretores / Conselhos de Gestão de Departamento 
Na qualidade de Diretor do Departamento, declaro que autorizo a execução do estudo de 
investigação acima mencionado e comprometo-me a prestar as condições necessárias 
para a boa execução do mesmo, de acordo com o programa de trabalhos e os meios 
apresentados. 
Departamento    Nome do Diretor  Data   
Assinatura 
Medicina              Rui Sarmento           ___/___/___ _______________ 
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Carta dirigida ao Presidente da Comissão de Ética para a Saúde do CHP a solicitar 
dispensa de consentimento informado 
Estudo de investigação: 
Safety of anti-TNF therapies in immune-mediated inflammatory diseases: focus on 
infections and malignancy 
Aluno da DIIC do curso de MIM do ICBAS/UP e do CHP:  
Rui Pereira 
 
Exma. Senhora Presidente da Comissão de Ética para a Saúde do CHP 
Rui Miguel Pedrosa Pereira, na qualidade de Aluno, vem por este meio, solicitar a Vossa 
Exa. dispensa do consentimento informado na realização do Estudo de Investigação acima 
mencionado visto este ser de carácter retrospetivo. No âmbito do mesmo o registo dos 
dados clínicos dos doentes (evidenciados em formulário em anexo) será feito com 
supervisão direta do tutor nas instalações do Serviço de Dermatologia do CHP e será 
anonimizado garantindo a confidencialidade dos dados. 
 
 
 
        Data       Assinatura 
___/___/_____   _________________________ 
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ANEXOS 
Documentos do projeto de investigação
  
 
  
  
 
 
  
  
 
 
